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Background: Rheumatoid arthritis (RA), a chronic autoimmune disease, affects
sufferers in many different ways. Treatment of this chronic condition is particularly
challenging. Traditional Chinese Medicine (TCM) provides alternatives. Bizhongxiao
decoction (BZX) is a TCM complex, which has been used clinically for many years to
treat RA. The purpose of this study is to compare the effects of BZX decoction and
its dismantled formulae on IL-1 and TNF-1 levels in rats with RA, and to elucidate its
mechanism of action.
Methods: Ninety healthy normal female SD rats were randomly divided into six
groups: normal (control), model, BZX decoction, and the three dismantled formulae
(I: heat-clearing and detoxication, II: dissipating dampness, and III: blood circulation
promotion). Apart from the normal (control) group, the rats in each group were
injected subcutaneously with bovine type II collagen and complete Freund adjuvant
to establish a collagen-induced arthritis model, so that inhibition of foot swelling in
the rats by BZX decoction and its dismantled formulae could be observed.
Immunohistochemistry was used to assess the levels of the inflammatory cytokines
IL-1 and TNF in synovial joints at various time points.
Results: Twenty-one days after the model was established, the levels of TNF and IL-1
were significantly higher in the model group, BZX decoction group and dismantled
formula groups I, II and III than in the normal controls (P < 0.05). The levels of these
cytokines were significantly higher in the model group than the BZX decoction or
the three dismantled formula groups (P <0.01). At longer times, the TNF and IL-1
levels in model group rose gradually; those in the BZX decoction and dismantled
formula groups were gradually reduced. The cytokine levels in the BZX decoction
group were lower than in the three dismantled formula groups and continued to
decline.
Conclusions: BZX decoction and the three dismantled formulae examined
down-regulated the inflammatory factors IL-1 and TNF in collagen-induced arthritis
rat models, but BZX exerted the strongest effect.
Keywords: Bizhongxiao decoction, Rheumatoid arthritis, Interleukin-1, Tumor
necrosis factor© 2012 Guo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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Rheumatoid arthritis (RA), a chronic autoimmune disease, affects sufferers in many dif-
ferent ways. RA can start in any joint, but it most commonly begins in the smaller
joints of the fingers, hands, and wrists. Other joints that are commonly affected include
hips, knees, ankles, feet, neck, shoulders, and elbows. Joint involvement is usually
symmetrical, both sides of the body being affected equally. In addition to joint pain
and inflammation, people with RA may suffer fatigue, occasional fevers, and a general
sense of not feeling well [1,2].
This type of arthritis is usually triggered by a viral infection or by an autoimmune
malfunction that can be attributed to many different causes. Treatment of this chronic
condition is particularly challenging because it is a systemic disease that usually affects
multiple joints, and a variety of immunocompetent cells, cytokines, and inflammatory
mediators are activated and participate in the pathogenic process. Interleukin-1 (IL-1)
and tumor necrosis factor-alpha (TNF) play key roles in the abnormal immune re-
sponse [3,4]. As it progresses, RA can result in a number of maladies including bone
deformity. The treatment will always include physical therapy, occupational therapy
and other strategies to enable the patient to cope with this debilitating disease. Any ap-
proach to choosing the correct medication for RA must involve the participation of a
medical professional. The seriousness of the condition coupled with the potentially ag-
onizing pain suffered by the patient calls for more potent medicine than can be offered
over the counter. Moreover, other types of prescription medication may be required to
combat other systems affected by the disease or the viral infection that triggered the
condition in the first place. Choosing the appropriate RA medication can be difficult
owing to the range of factors that contribute to the development of the disease. Medi-
cations used include disease-modifying anti-rheumatic drugs (DMARDs) such as
Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine sulfate and Azathiop-
rine. These can also be described as slow-acting anti-rheumatic drugs (SAARDs). They
suppress inflammation and may also retard the development of joint erosions. The exact
reason why they are effective is not currently well understood.
Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed as pain killers and
include ibuprofen and naproxens. They may also ameliorate inflammatory forms of
arthritis such as RA. They have no effect on the progress of the disease but may relieve
symptoms. The use of NSAIDs is often limited because they increase the risk of upper
gastrointestinal problems such as gastric ulcers. COX-2-specific inhibitors such as cele-
coxib are also non-steroidal anti-inflammatory agents. They are effective in reducing
inflammation and relieving pain and are far gentler on the stomach than the conven-
tional, older NSAIDs. However, coxibs may be associated with an increased risk of
cardiovascular events. Corticosteroids such as prednisone and Prednisolone reduce in-
flammation and suppress the immune system. These agents are used in the treatment of
RA, both as tablets and as injections into the affected joint. Prednisolone is sometimes
used in moderate to severe RA where NSAIDs and DMARDs fail to control the
disease. Biological agents, a new category of arthritis treatments called tumor necrosis
factor (TNF) inhibitors, have been developed. Infliximab (otherwise Remicade) is a
TNF inhibitor available for the treatment of RA in selected patients. It slows the pro-
gression of the disease and reduces joint injury. It is given along with Methotrexate.
There is also promising work in the field of stem cell research, indicating that new
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joints; however, this work is still at an early stage of development.
Bizhongxiao decoction (BZX) is prescription for RA with which our department has
experience. Many years of clinical practice have shown that it is effective against RA in
the long term and has no significant side effects [5,6]. In this study, we investigated the
mechanism of action of BZX and its dismantled formulae in RA treatment and its
effect on the IL-1 and TNF levels in a type II collagen-induced rat arthritis model.Materials and methods
Materials and reagents
Ninety healthy female SD rats aged 45-50 days, body weight 180 ± 20 g, were provided
by the Experimental Animal Center of Xiangya Medical School. Complete Freund's
adjuvant, bovine type II collagen, and IL-1 and TNF kits were purchased from AB
Company (China). Para formaldehyde, PBS, 18 cm stainless steel pressure cooker, bath,
electric oven, dip wax cup, and slicer were provided by our laboratory.
BZX consisted of Hedyotis diffusa, Herba sarcandrae, Semen coicis, Savia miltiorrhiza,
Chinese star jasmine stem, Rhizoma drynariae; Heat-clearing and detoxication formula
(dismantled group I) consisted of Hedyotis diffusa, Herba sarcandrae, Radix actinidiae;
Dissipating dampness formula (dismantled group II) consisted of Semen coicis, Chinese
star jasmine stem,Viciaamoena Fisch; Blood circulation promotion formula (dismantled
group III) consisted of Savia miltiorrhiza, Herba sarcandrae and Radix actinidiae.
Chinese medicine dosage for the rats (200 g) was calculated in proportion to humans
(70 kg) using body surface area conversion; each gavage was 18.6 g/kg d. All crude
drugs were purchased from Central South University Xiangya Hospital pharmacy and
the quality agreed with the People's Republic of China Pharmacopoeia (2005). The four
Chinese medicine compounds were processed as follows: they were mixed, soaked for
1 h, and boiled twice in a multi-function extraction tank (volume of water added was
8 or 10 times the crude medicine, boiled for 1.5 h or 1 h, respectively). The two filtrates
were merged and then evaporated to a thick extract, vacuum dried, crushed to a dry
extract powder, dispensed, placed in a vacuum dryer, sealed and stored in a cool place.Animal grouping
Using a random number table, the animals were divided into six groups (n = 15 in
each): normal (control) group, model group, Bizhongxiao decoction group, dismantled
group I, dismantled group II, dismantled group III.Experimental animal arthritis model
According to the method of Deng Anmei [7], 90 SD rats, all female, age 40 ~ 50 d, body
weight (180 ± 10 g) received food ad libitum and were housed with a 12 h/12 h light/
dark cycle (exposure time 6:00 ~ 18:00) at 20 ± 3°C for one week to allow them to adapt
to the environment. Background noise was 40 ± 10 db. Fifteen rats were randomly
selected as the normal (control) group; the remaining 75 were used for modeling.
Bovine type II collagen (CII) (10 mg) was mixed with 5 mL of 0.1 mol L-1 acetic acid,
giving a CII concentration of 2 g L-1. The solution was kept at 4°C in a refrigerator over-
night. For the experiments, it was mixed 1:1 with Freund's complete adjuvant in an
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centration = 1 g L-1) was injected intradermally into the rat in the left rear foot, the
back, and the base of the tail. To enhance the reaction, the injections were repeated at
day 21, this time into the right rear foot, the back, and the base of the tail.Delivery methods
From day 15 of the experiment, either BZX extract or one of the three dismantled
formulae was administered orally to the rats in the four treatment groups, and this
treatment continued daily by gavage for 14 days. The other groups were gavage with
distilled water. All the rats were fed normally and had free access to water.Arthritis index scores
After paw swelling appeared, the arthritis index (AI) scores were assessed every four days
by five independent judges [8]. These scores indicate the degree and range of joint swel-
ling and deformation. A five-point scale was used to calculate the AI. 0: no swelling; 1: toe
joint swelling; 2: toe joint and toe swelling; 3: paw edema below the ankle; 4: paw swelling
including the ankle. The scores for individual limbs and joints were summed to obtain the
final total score; the higher the AI score, the more serious the joint symptoms.Synovial tissue immunohistochemistry
The rats in each of the six study groups were randomly divided into three sub-groups.
On days 14, 21, 28 after the initial CII injection, the rats in one subgroup of each group
were killed and the knee and ankle joints were carefully stripped. Synovium sections
were fixed with 10% neutral formalin and paraffin-embedded for HE staining and
immunohistochemical observation. The sections were examined in accordance with the
kit instructions for testing. Three fields (× 400) selected for each tissue slice were used
for Bio Mias computer software image processing; the signal strength was analyzed to
calculate the total amount of positive staining of the target.Statistical analysis
All data were expressed as mean ± SD. A single factor analysis of variance and a Kronbach
α test were applied to the different groups. SPSS 13 software was used for statistical analysis.Results
General observation
The CII model rats after the initial injection ate less and the average body weight was
reduced by 30 ± 10 g. Later, the fur grew dull and the ankle and toe joints developed
various degrees of swelling; the first onset was in the hind legs. All 75 CII-injected rats
showed symptoms of arthritis. On day 7 after the initial injection, some joint swelling
and ecchymosis was observed and mild swelling occurred in the left hind paw. On day
10 the ankle toe joints and the left hind paw swelling gradually worsen, and some of
the articular surface skin appeared shiny and congested. At day 21 after re-injection,
the arthritis symptoms of the rats worsened and swelling was observed in the right hind
paw. Up to day 28, some of the rats showed limited joint activity and the hind paw
swelling increased. One week after treatment began, the joint swelling was gradually
Figure 1 Model group, the BZX Group, dismantled group I, II, III arthritis index scores.
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shrunk slightly, there was decreased reddening of the toes, and the fur was less dull
than in the model group.
Assessment of arthritis index scores
Figure 1 showed the arthritis index scores of model group, the BZX Group, dismantled
group I, II, III. There were no significant differences in AI scores among the five
CII-injected groups during the first 14 days following the initial injection. The score of
the model group continued to increase and reached a peak on day 28 following the ini-
tial injection. The scores in the three dismantled groups also reached peaks (20 ± 5 days)
but they were lower than the model group peak, and the AI score gradually decreased
thereafter. The score for the BZX rats reached its peak at d 20, still lower than the model
group, and then showed a gradual steady decline so that it was lower at each time point
than the scores for the dismantled groups. On day 28, when the joint inflammation
index was lowest, the difference was significant (P < 0.05).
Synovial tissue TNF expression and effects in the BZX and dismantled groups
Table 1 shows that the serum TNF in the model group followed an increasing trend
and was significantly higher than that in the control group (P < 0.05); the rats in the
model group showed an obvious inflammatory response. In the BZX and the threeTable 1 TNF expression in collagen-induced arthritic rat synovial tissue (mean ± SD)
Groups TNF
14d 21d 28d
Normal 180 ± 44 180 ± 44 180 ± 44
Model 180 ± 44* 368 ± 81* 485 ± 93*
Bizhongxiao 178 ± 45* 208 ± 28 * 103 ± 24*
Dismantled I 180 ± 43* 248 ± 74 * 197 ± 37*
Dismantled II 177 ± 39* 296 ± 24* 205 ± 45*
Dismantled III 181 ± 41* 312 ± 13* 268 ± 28*
Note: *compared with normal group, P < 0.05; and compared to the same point in time the model group, P < 0.05;
compared to prior time points among groups, P < 0.05; compared to the same time points with dismantled formula
groups, P < 0.05.
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that in the model group (P < 0.05); the down-regulation was more obvious in the BZX
group. TNF expression in the BZX group at days 21, 28 was lower than in dismantled
groups I, II and III (P < 0.05) but still higher than in the normal control group
(P < 0.05). The TNF level in dismantled group I was lower than that in dismantled group
II, which in turn was lower than that in dismantled group III (P < 0.05). These findings
suggested that the treatment outcome should be in the order dismantled group I > dis-
mantled group II > dismantled group III. Figure 2 shows the success of the rat RA
model and the greater or lesser down-regulation of TNF in the BZX and dismantled
groups.Normal group (14 d) Normal group (21 d) Normal group (28 d) 
Model group (14d) Model group (21d) Model group (28d) 
BZX group (14d) BZX group ( 21d) BZX group (28d) 
Dismantled group I (14d) Dismantled group I (21d) Dismantled group I (28d) 
Dismantled group II (14d) Dismantled group II (21d) Dismantled group II (28d) 
Dismantled group III (14d) Dismantled group III (21d) Dismantled group III (28d) 
Figure 2 Immunochemical slices after immunication with TNF in AA rats.
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groups
From Table 2, serum IL-1 in the model group increased with time and was significantly
higher than that in the control group (P < 0.05), again indicating an obvious inflammatory
response. In the BZX and the three dismantled groups, the serum IL-1 was down-
regulated and significantly lower than that in the model group (P < 0.05); the down-
regulation was more obvious in the BZX group. IL-1 expression in the BZX group at
days 21, 28 was lower than in dismantled groups I, II and III (P < 0.05) but still higher
than in the normal control group (P < 0.05). The IL-1 level in dismantled group I was
lower than that in dismantled group II, which in turn was lower than that in dismantled
group III (P < 0.05). These findings suggested that the treatment outcome should be in
the order dismantled group I > dismantled group II > dismantled group III. Figure 2
shows the success of the rat RA model and the greater or lesser down-regulation of
IL-1 in the BZX and dismantled groups.Discussion
Rheumatoid arthritis (RA) is a systemic autoimmune disease whose cause is not yet
fully elucidated, the main symptoms being chronic synovitis and structural joint injury.
The current study suggests that cytokines play an important role in the pathogenesis of
RA. Cytokines are a class of biologically active substances synthesized and secreted by
immune cells and some non-immune cells receiving the appropriate stimulation, and
they modulate various cell physiological functions. Studies have confirmed that in RA,
large amounts of cytokines are secreted by synovial cells and by monocytes/macrophages
and lymphocytes that infiltrate the synovial tissue. These cytokines form a complex
network by acting on a variety of cells and adjusting each other’s levels. Imbalance in
this network promotes the occurrence and development of RA [9]. Interleukin-1 (IL-1)
and TNF play a decisive role in the progression of RA [10]. There are two isoforms of
IL-1, IL-1α and IL-1β, IL-1β being instrumental in cartilage damage in RA. Its main role
is to promote the proliferation and differentiation of synovial cells and lymphocytes,
stimulating synovial cells and cartilage cells to synthesize and release prostaglandin E2
(PGE2) and collagenase, causing synovial inflammation and disintegration of the cartilage
matrix [11,12]. In addition, IL-1 can stimulate synovial cells and cartilage cells to
synthesize excess metalloproteinases, but it also promotes the release of PhospholipaseTable 2 IL-1 expression in collagen-induced arthritic rat synovial tissue (mean ± SD)
Groups IL-1
14d 21d 28d
Normal 226 ± 29 226 ± 29 226 ± 29
Model 227 ± 29* 384 ± 73* 483 ± 43*
Bizhongxiao 227 ± 17* 277 ± 79* 248 ± 40*
Dismantled I 226 ± 28* 288 ± 28* 263 ± 20*
Dismantled II 227 ± 29* 315 ± 38* 283 ± 20*
Dismantled III 227 ± 25* 333 ± 36* 308 ± 28*
Note: *compared with normal group, P <0.05; and compared to the same point in time the model group, P <0.05;
compared to prior time points among groups, P <0.05; compared to the same time points with dismantled formula
groups, P <0.05.
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sor glycosaminoglycans, and inhibits the mitotis-promoting activity of various growth
factors on the chondrocytes, thereby enhancing the destruction of the cartilage matrix.
Of the TNF isoforms, TNF-α and TNF-β, TNF-α is most closely implicated in RA. It has
a similar role to IL-1, stimulating absorption of the cartilage proteoglycan and inhibiting
its synthesis, enhancing the degradation of cartilage, and stimulating synovial cells and
cartilage cells to synthesize PGE2 and collagenase to cause absorption of bone and
cartilage destruction [13]. TNF promotes the formation of osteoclasts, increases their
activity, and prolongs their survival, thereby contributing to focal bone erosion in RA.
The biological effects of TNF and IL-1 are coordinated and these cytokines act syner-
gistically in most cases. IL-1 is related to the destruction of articular cartilage while
TNF-α is mainly involved in the regulation of inflammation [14].
This study demonstrates that on day 25 after modeling, significant joint swelling
appeared, and TNF and IL-1 levels were significantly increased and continued to in-
crease gradually with the progress of the disease. After BZX treatment, the TNF and
IL-1 levels decreased and the joint swelling showed various degrees of relief, demon-
strating the importance of inhibiting these two cytokines in RA treatment.
RA belongs to the "Arthralgia" category in Chinese medicine, but is also called
"Arthromyodynia" and "joint-running wind". Its specific etiology and dialectical type
pathogenesis are not entirely uniform. Those involved in its management are more
focused on the basis of traditional Chinese medicine theory combined with their own
clinical experience for differential diagnosis and treatment [15-17].
RA is mostly considered to belong to the same areas of medicine as rheumatic fever,
paralysis, the pathogenesis of viscera injuries. Yin and yang imbalance is the inherent
basis, and the preconditions are caught cold, hot and humid, toxin disease outside.
Toxicity, heat, moisture, and blood stasis are generally believed to be the pathological
factors. After a complex pathological process, these factors result in toxin accumula-
tion, heat production, phlegm blockage, blockage of the meridian and final formation
of the disease.
BZX is produced by Professor Liang Qing-hua for the long-term treatment of active
RA. Previous work suggested it significantly inhibits vascular endothelial growth factor
expression in affected rat synovial joints [18] and regulates T cell subsets [19]; treat-
ment of active RA with BZX had a good outcome, improving the patients’ morning
stiffness, joint pain, joint swelling, and joint tenderness more rapidly than Methotrexate
[20]. The rats in the experiment described in the present paper were in the active stage
of RA development, and the serum IL-1 and TNF levels were reduced to different
degrees in the BXZ group and dismantled groups. The cytokine levels were sufficiently
reduced in the BXZ group to approach the normal range; the dismantled groups
showed a lesser effect. Synergistic actions among these groups, which affect different
aspects of the inflammatory disorder, are obvious. In active RA, heat and toxicity are
the main factors. This study indicates that BZX has heat-clearing and detoxication
effects, promotes blood circulation, eliminating wind and dredging channels, dissipating
dampness for detumescence, and regulating cytokines in order to diminish inflammation
in the rats, gradually reducing joint injury. It was then clear that the anti-inflammatory
effect of BZX was closely related to the inhibition of inflammatory cytokine production.
BZX slows or blocks the proinflammatory effects of inflammatory cytokines and
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mal secretion of IL-1 and TNF, thus reducing inflammation, accelerates the clearance
of the inflammatory cytokines, inhibits synovial cell proliferation, and inhibits acti-
vated B cells and T cells so as to reduce inflammation and destruction of the synovial
tissue. Thus it interrupts the pathological process of RA in rats, and in turn affects
the occurrence and development of inflammation. This study further reveals the role
of the anti-inflammatory effect of BZX in the experimental rats. Figure 3 showed the
results of immunochemical slices after immunication with IL-1 in AA rats. How BZXNormal group (14 d) Normal group (21 d) Normal group (28 d) 
Model group (14d) Model group (21d) Model group (28d) 
BZX group (14d) BZX group ( 21d) BZX group (28d) 
Dismantled group I (14d) Dismantled group I (21d) Dismantled group I (28d) 
Dismantled group II (14d) Dismantled group (II 21d) Dismantled group II (28d) 
Dismantled group III (14d) Dismantled group III (21d) Dismantled group III (28d) 
Figure 3 Immunochemical slices after immunication with IL-1 in AA rats.
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the experimental rats will be further studied in future experiments.
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